JP2013542241A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542241A5
JP2013542241A5 JP2013538215A JP2013538215A JP2013542241A5 JP 2013542241 A5 JP2013542241 A5 JP 2013542241A5 JP 2013538215 A JP2013538215 A JP 2013538215A JP 2013538215 A JP2013538215 A JP 2013538215A JP 2013542241 A5 JP2013542241 A5 JP 2013542241A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutically acceptable
acceptable salt
cancer
alkylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538215A
Other languages
English (en)
Japanese (ja)
Other versions
JP6382516B2 (ja
JP2013542241A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/069976 external-priority patent/WO2012062920A1/en
Publication of JP2013542241A publication Critical patent/JP2013542241A/ja
Publication of JP2013542241A5 publication Critical patent/JP2013542241A5/ja
Application granted granted Critical
Publication of JP6382516B2 publication Critical patent/JP6382516B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538215A 2010-11-12 2011-11-11 抗腫瘍アルカロイドを用いる、組み合わせの治療法 Active JP6382516B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382300.1 2010-11-12
EP10382300 2010-11-12
PCT/EP2011/069976 WO2012062920A1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016092369A Division JP6723815B2 (ja) 2010-11-12 2016-05-02 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Publications (3)

Publication Number Publication Date
JP2013542241A JP2013542241A (ja) 2013-11-21
JP2013542241A5 true JP2013542241A5 (OSRAM) 2014-12-25
JP6382516B2 JP6382516B2 (ja) 2018-08-29

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013538215A Active JP6382516B2 (ja) 2010-11-12 2011-11-11 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2016092369A Active JP6723815B2 (ja) 2010-11-12 2016-05-02 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059776A Active JP6724055B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059777A Active JP6724056B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016092369A Active JP6723815B2 (ja) 2010-11-12 2016-05-02 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059776A Active JP6724055B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法
JP2018059777A Active JP6724056B2 (ja) 2010-11-12 2018-03-27 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Country Status (24)

Country Link
US (5) US20130266666A1 (OSRAM)
EP (6) EP2786756B1 (OSRAM)
JP (4) JP6382516B2 (OSRAM)
KR (9) KR20170096065A (OSRAM)
CN (3) CN105664165A (OSRAM)
AU (4) AU2011328004C1 (OSRAM)
BR (4) BR122017028568B1 (OSRAM)
CA (4) CA2995033C (OSRAM)
CY (4) CY1117466T1 (OSRAM)
DK (4) DK2786756T3 (OSRAM)
ES (4) ES2719091T3 (OSRAM)
HK (1) HK1202422A1 (OSRAM)
HR (4) HRP20160361T1 (OSRAM)
HU (4) HUE042801T2 (OSRAM)
LT (3) LT2786753T (OSRAM)
ME (3) ME02395B (OSRAM)
PL (4) PL2786754T3 (OSRAM)
PT (3) PT2786754T (OSRAM)
RS (4) RS60236B1 (OSRAM)
RU (4) RU2605335C2 (OSRAM)
SI (4) SI2637663T1 (OSRAM)
SM (4) SMT201900190T1 (OSRAM)
TR (2) TR201903859T4 (OSRAM)
WO (1) WO2012062920A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
LT2786753T (lt) * 2010-11-12 2019-04-10 Pharma Mar S.A. Derinių terapija su antinavikiniu antibiotiku
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
WO2016120853A1 (en) * 2015-01-30 2016-08-04 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
CA3239447A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
AU2020342483A1 (en) * 2019-09-03 2022-04-14 Pharma Mar, S.A. Lurbinectedin in the treatment of malignant mesothelioma
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
AU2020388196B2 (en) * 2019-11-21 2025-08-14 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
JP7669053B2 (ja) * 2020-07-01 2025-04-28 ニュー キャンサー キュア－バイオ カンパニー リミテッド ３－ケトアシルｃｏａタイオレース阻害剤とカルニチンアシルカルニチンキャリア阻害剤を含む癌の予防または治療のための医薬組成物
CN118576611A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗尤文氏肉瘤的药物中的用途
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN115957188A (zh) * 2021-06-17 2023-04-14 中国医学科学院医药生物技术研究所 米铂脂质体在抗耐药性肿瘤的应用
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof
WO2024188978A1 (en) * 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
WO2025228597A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
WO1987007610A2 (en) 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
PT1067933E (pt) 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
CZ302168B6 (cs) 1998-05-11 2010-11-24 Pharma Mar, S. A. Metabolity ecteinascidinu 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001053299A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
AU784249C (en) 2000-04-12 2007-05-03 Pharma Mar S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
SK287901B6 (sk) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP3835763B2 (ja) 2002-08-19 2006-10-18 ファイザー・プロダクツ・インク 増殖亢進疾患のための組み合わせ治療
CA2501089C (en) 2002-10-18 2012-07-17 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
CA2566156A1 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Method for treating abnormal cell growth
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
SI1827437T1 (sl) * 2004-12-15 2012-02-29 Sigma Tau Ind Farmaceuti Kombinacije terapevtskih sredstev za zdravljenje raka
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
RS54928B1 (sr) * 2006-02-28 2016-10-31 Pharma Mar Sa Poboljšano lečenje multiplog mijeloma
KR20110025178A (ko) * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
LT2786753T (lt) * 2010-11-12 2019-04-10 Pharma Mar S.A. Derinių terapija su antinavikiniu antibiotiku

Similar Documents

Publication Publication Date Title
JP2013542241A5 (OSRAM)
RU2013126630A (ru) Комбинированная терапия противоопухолевым алкалоидом
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2011520921A5 (OSRAM)
JP2007277240A5 (OSRAM)
JPWO2023011631A5 (OSRAM)